Tradestie Institutional Equity Comparison Engine

RGNX vs CGON โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CGON Overall Edge

CGON Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CG Oncology, Inc. Common stock (CGON) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while RGNX counters with relative strength in Valuation. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus CGON at N/M Forward P/E and -4293.5% operating margin (-3.7% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against CGON sits in CONSOLIDATION (85th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner RGNX
RGNX N/M vs CGON N/M Fwd P/E
Growth & Margin Winner CGON
Op Margin -120.4% vs -4293.5% ยท YoY -69.2% vs -3.7%
Momentum & Technical Winner CGON
1Y -36.0% vs +124.9% ยท 52W Pos 19% vs 84%
Options & Structure Winner CGON
BREAKDOWN (52nd %ile IV) vs CONSOLIDATION (85th %ile IV)
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.45
-2.49% 1D
Market Cap $500.9M
1M Return +7.58%
1Y Return -36.0%
Forward P/E N/M
Unified AI Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
CGON NASDAQ
CG Oncology, Inc. Common stock
Biological Products, (No Disgnostic Substances)
$84.94
+14.16% 1D
Market Cap $6.3B
1M Return +41.91%
1Y Return +124.93%
Forward P/E N/M
Unified AI Score
45.0 / 100 HOLD
Tech 15.0 Fund 44.0 Flow 69.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: RGNX -36.0% CGON +124.93% Spread: +160.93 pp (CGON Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period RGNX Revenue CGON Revenue RGNX Op. Margin CGON Op. Margin Margin Edge
FY2018 $220M N/A 40.3% N/A RGNX
FY2019 $40M N/A -422.9% N/A RGNX
FY2020 $150M N/A -77.1% N/A RGNX
FY2021 $470M N/A 34.0% N/A RGNX
FY2022 $110M N/A -233.2% N/A RGNX
FY2023 $90M $0M -297.1% -27180.9% RGNX
FY2024 $80M $0M -280.0% -10067.3% RGNX
FY2025 $170M $0M -94.6% -4722.1% RGNX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: RGNX (3) vs CGON (5)
Institutional Metric RGNX CGON Criterion Row Winner
Market Capitalization Scale $500.9M $6.3B Larger Scale CGON
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -69.2% -3.7% Higher Growth CGON
Operating Margin (TTM) Profitability -120.4% -4293.5% Higher Margin RGNX
Net Profit Margin Profitability -113.9% 0.0% Higher Margin CGON
Return on Equity (ROE) Capital Efficiency -113.2% -28.3% Higher ROE CGON
52-Week Range Position Momentum 19% ($5โ€“$16) 84% ($37โ€“$94) Stronger Trend CGON
Beta / 30D Volatility Risk Regime 1.82ฮฒ ยท 76% Vol 0.77ฮฒ ยท 86% Vol Lower Realized Risk RGNX
Unified Institutional Score Composite Signal 45.3 / 100 (HOLD) 45.0 / 100 (HOLD) Higher Composite RGNX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full RGNX vs CGON Buy Guide
RGNX BREAKDOWN
91d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 52nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live RGNX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CGON CONSOLIDATION
62d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 85th %ile
IV Regime Extreme (>80th %ile)
Live CGON Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither RGNX nor CGON registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.